Prolongation of pregnancy in preeclampsia by therapeutic lipid-apheresis and its effect on fetal lipid metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00004527

Enrollment

Registered

2013-06-04

Start date

2013-04-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

O14.9

Interventions

Group 1: 15 preeclamptic patients will be treated with H.E.L.P. apheresis or double filtration apheresis (case group) Group 2: 15 pregnant women without preeclampsia (control group) Group 3: cord bloo

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnant women with early preeclampsia ( 18 years

Exclusion criteria

Exclusion criteria: Pregnant women: every acute indication for immediate delivery; fetal blood cord: every medical reason against the blood withdrawal

Design outcomes

Primary

Measure	Time frame
Prolongation of pregnancy	—

Secondary

Measure	Time frame
Pregnant women with apheresis (case group): proteinuria, blood pressure, clinical symptoms, sonographic criteria in doppler ultrasound of umbilical vessels, quantity of amniotic fluid, concentrations of lipoproteins seperated by density gradient ultracentrifugation, fibrinogen, sFlt-1 und PlGF, Lp-PLA2, blood cell count, haptoglobin, serum kreatinine, GOT, GPT, blood viscosity; in vitro: effect of biochemical parameters and diverse lipoprotein fractions on vasoactive receptors in cell cultures, analysis of parameters in the eluate of the apheresis filter; pregnant women (control group): concentrations of lipoproteins seperated by density gradient ultracentrifugation, fibrinogen, sFlt-1 und PlGF, Lp-PLA2, blood cell count, differential blood count, haptoglobin, serum kreatinine, GOT, GPT, blood viscosity; cord blood (case and control group): pH,total cholesterol, triglycerides, lipidelectrophoresis, lipid density gradient ultracentrifugation, Lp(a), Lp-PLA2, sFLT, PlGF; newborn (case group): weight, body height, pH of umbilical cord blood, APGAR, severe respiratory distress syndrome, duration of mechanical ventilation, intracranial hemorrhage (grade 1-4), necrotising enterocolitis, sepsis, duration of stay in intensive care unit, need of surfactant; newborn (control group): weight, body height, APGAR	—

Measure

Time frame

Pregnant women with apheresis (case group): proteinuria, blood pressure, clinical symptoms, sonographic criteria in doppler ultrasound of umbilical vessels, quantity of amniotic fluid, concentrations of lipoproteins seperated by density gradient ultracentrifugation, fibrinogen, sFlt-1 und PlGF, Lp-PLA2, blood cell count, haptoglobin, serum kreatinine, GOT, GPT, blood viscosity; in vitro: effect of biochemical parameters and diverse lipoprotein fractions on vasoactive receptors in cell cultures, analysis of parameters in the eluate of the apheresis filter; pregnant women (control group): concentrations of lipoproteins seperated by density gradient ultracentrifugation, fibrinogen, sFlt-1 und PlGF, Lp-PLA2, blood cell count, differential blood count, haptoglobin, serum kreatinine, GOT, GPT, blood viscosity; cord blood (case and control group): pH,total cholesterol, triglycerides, lipidelectrophoresis, lipid density gradient ultracentrifugation, Lp(a), Lp-PLA2, sFLT, PlGF; newborn (case group): weight, body height, pH of umbilical cord blood, APGAR, severe respiratory distress syndrome, duration of mechanical ventilation, intracranial hemorrhage (grade 1-4), necrotising enterocolitis, sepsis, duration of stay in intensive care unit, need of surfactant; newborn (control group): weight, body height, APGAR

—

Countries

Germany

Contacts

Public ContactBrigitte König

Universitätsklinikum Freiburg, Institut für Klinische Chemie und Laboratoriumsmedizin

brigitte.koenig.zentrallabor@uniklinik-freiburg.de0761/270-77210

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 6, 2026